Cross-sex hormone treatment of transgender adults leads to very few long-term side effects, according to the authors of the largest study to date to examine this issue.
“when using the guidelines from the Endocrine Society [“Endocrine Treatment of Transsexual Persons”], you are not going to see a lot of comorbidities with cross-sex hormone treatment.”

At entry into the study (baseline), the most common comorbidity in both groups was depression, with a 24.9% incidence in MTF subjects and 13.6% in FTM. Even after treatment, 26 (2.4%) of the MTF subjects and 7 (1.4%) of the FTM subjects still reported depression, leading Dr. Asscheman to tell the large audience, “Sex-reassignment treatment does not cure depression.”

Another comorbidity before transgender hormonal therapy is hypothyroidism. Hypothyroidism is also associated with depression.

Please treat your depression as another part of your health.